Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 4/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25601320 | 0.93 | NOTUM (0.42) | NOTUMHTR2CSYKCHRNB2CHRNA4 | |
| SCHEMBL16957247 | 0.85 | NOTUM (0.54) | NOTUMHTR2CSYKCHRNB2CHRNA4 | |
| SCHEMBL22864314 | 0.81 | CHRNB2 (0.37) | NOTUMHTR2CSYKCHRNB2CHRNA4 | |
| SCHEMBL24728251 | 0.80 | RBP4 (0.50) | RBP4SLC6A3 | |
| SCHEMBL13141203 | 0.79 | NOTUM (0.49) | NOTUMHTR2CSYKCHRNB2CHRNA4 | |
| SCHEMBL22083833 | 0.78 | NOTUM (0.48) | NOTUMHTR2CSYKCHRNB2CHRNA4 | |
| SCHEMBL18946083 | 0.78 | NOTUM (0.48) | NOTUMHTR2CSYKCHRNB2CHRNA4 | |
| SCHEMBL21466401 | 0.78 | NOTUM (0.46) | NOTUMHTR2CCHRNB2CHRNA4RBP4 | |
| SCHEMBL18394277 | 0.77 | GAA (0.48) | NOTUMHTR2CCHRNB2CHRNA4RBP4 | |
| SCHEMBL24633967 | 0.77 | KDM1A (0.49) | NOTUMHTR2CRBP4PTGDR2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234951-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2023-07-27 | — | — | US | disclosed |
| WO-2019191166-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2017155844-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | NOTUM 2866/4885HTR2C 4660/4885SYK 3785/4885 |
| US-20230234951-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | CYCS, CYP2E1, AHR | NOTUM 2199/4885HTR2C 1794/4885SYK 779/4885 |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | NOTUM 3131/4885HTR2C 4713/4885SYK 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.